[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100652019":3},{"organization":4,"armGroups":7,"interventions":22,"overallOfficials":27,"centralContacts":32,"locations":41,"responsibleParty":150,"collaborators":152,"id":154,"slug":155,"hasResults":156,"nctId":157,"briefTitle":158,"officialTitle":159,"acronym":160,"eligibilityCriteria":161,"healthyVolunteers":162,"sex":163,"minAge":164,"maxAge":18,"enrollmentInfo":165,"targetDuration":18,"studyType":168,"phases":169,"briefSummary":171,"conditions":172,"keywords":174,"overallStatus":179,"whyStopped":18,"lastUpdateSubmitDate":180,"lastUpdatePostDateStruct":181,"startDateStruct":184,"completionDateStruct":186,"leadSponsor":188,"locationsCount":189},{"fullName":5,"class":6},"King's College Hospital NHS Trust","OTHER",[8,14,19],{"label":9,"type":10,"description":11,"interventionNames":12},"Mindfulness","EXPERIMENTAL","The intervention consists of consists of an 8-week self-directed daily mindfulness course, combined with fortnightly group mindfulness sessions that participants are encouraged to join from enrolment up until their month 6 follow up visit. The intervention has been designed specifically for this trial and is tailored to central serous chorioretinopathy.\n\nParticipants will be given a set of video and audio guidance for daily mindfulness-based practices, for a total duration of 8 weeks, alongside a 'road map' of the intervention to prompt them to which practices to use on each day. Daily practices will include body scan exercises, breathing exercises, mindful movement, mindful moments in daily life exercises, and mindfulness in response to stress exercises. Practices will range from 5 - 20 minutes' duration. Participants will be invited to join fortnightly group mindfulness calls, held via Microsoft Teams, for the first six months of their involvement in the trial.",[13],"Behavioral: Mindfulness",{"label":15,"type":16,"description":17,"interventionNames":18},"No mindfulness","NO_INTERVENTION","This is the control group. They will not undertake daily mindfulness practices or fortnightly group sessions.",null,{"label":20,"type":16,"description":21,"interventionNames":18},"No central serous chorioretinopathy (healthy eyes)","This arm is the case-control comparator, consisting of age- and sex-matched adults with no central serous chorioretinopathy or other sight-threatening eye conditions",[23],{"type":24,"name":9,"description":25,"armGroupLabels":26,"otherNames":18},"BEHAVIORAL","The intervention is an 8 week course of daily mindfulness practices, accompanied by 6 months of fortnightly group sessions. Two introductory videos will explain about central serous chorioretinopathy, mindfulness and the links both have to stress-related factors, and outline the structure of the mindfulness course. Participants will be given a set of video and audio files that will guide them through daily mindfulness practices, for a total duration of 8 weeks. Daily practices will include body scan exercises, breathing exercises, mindful movement, mindful moments in daily life exercises, and mindfulness in response to stress exercises. Individual practices will range from 5 - 20 minutes' duration. There will also be fortnightly group mindfulness sessions, facilitated by a mindfulness coach and with an Ophthalmologist present. They will include guided mindfulness practices and free discussion time for participants to share their experience of the intervention and ask questions.",[9],[28],{"name":29,"affiliation":30,"role":31},"Timothy Jackson","King's College London","PRINCIPAL_INVESTIGATOR",[33,38],{"name":34,"role":35,"phone":36,"phoneExt":18,"email":37},"Olivia Cundy, BA, BMBCh","CONTACT","02032997791","olivia.cundy@nhs.net",{"name":39,"role":35,"phone":18,"phoneExt":18,"email":40},"King's Ophthalmology Research Unit","kch-tr.ophthalmologyresearch@nhs.net",[42,64,83,102,118,134],{"facility":43,"status":18,"city":44,"state":18,"zip":45,"country":46,"countryCode":47,"cosmosGeoPoint":48,"geoPoint":53,"contacts":54},"Bristol Eye Hospital","Bristol","BS1 2LX","United Kingdom","UK",{"type":49,"coordinates":50},"Point",[51,52],-2.59665,51.45523,{"lat":52,"lon":51},[55,59,62],{"name":56,"role":35,"phone":57,"phoneExt":18,"email":58},"Eleanor Hiscott","01173424770","Eleanor.Hiscott@uhbw.nhs.uk",{"name":60,"role":35,"phone":18,"phoneExt":18,"email":61},"Clinical Research Unit Manager","BEHCRUManagers@uhbw.nhs.uk",{"name":63,"role":31,"phone":18,"phoneExt":18,"email":18},"Lina Kobayter Helayhel",{"facility":65,"status":18,"city":66,"state":18,"zip":67,"country":46,"countryCode":47,"cosmosGeoPoint":68,"geoPoint":72,"contacts":73},"Kent and Canterbury Hospital","Canterbury","CT1 3NG",{"type":49,"coordinates":69},[70,71],1.07992,51.27904,{"lat":71,"lon":70},[74,78,81],{"name":75,"role":35,"phone":76,"phoneExt":18,"email":77},"Amy Kenyon","01227783172","amykenyon@nhs.net",{"name":79,"role":35,"phone":18,"phoneExt":18,"email":80},"Caroline Cowley","ekhuft.researchandinnovation@nhs.net",{"name":82,"role":31,"phone":18,"phoneExt":18,"email":18},"Nadir Ali",{"facility":84,"status":18,"city":85,"state":18,"zip":86,"country":46,"countryCode":47,"cosmosGeoPoint":87,"geoPoint":91,"contacts":92},"Clinical Eye Research Centre, St Paul's Eye Unit, Liverpool University Hospitals NHS Trust","Liverpool","L7 8YE",{"type":49,"coordinates":88},[89,90],-2.97794,53.41058,{"lat":90,"lon":89},[93,97,100],{"name":94,"role":35,"phone":95,"phoneExt":18,"email":96},"Florina Caban","01517063798","florina.caban@liverpoolft.nhs.uk",{"name":98,"role":35,"phone":18,"phoneExt":18,"email":99},"Ian Pearce","ian.pearce@liverpoolft.nhs.uk",{"name":101,"role":31,"phone":18,"phoneExt":18,"email":18},"Nicholas Beare",{"facility":103,"status":18,"city":104,"state":18,"zip":105,"country":46,"countryCode":47,"cosmosGeoPoint":106,"geoPoint":110,"contacts":111},"King's College London Frost Eye Departent, Guys' and St Thomas' Hospital","London","SE1 7EH",{"type":49,"coordinates":107},[108,109],-0.12574,51.50853,{"lat":109,"lon":108},[112,116],{"name":113,"role":35,"phone":114,"phoneExt":18,"email":115},"Humra Chadwick","02071884885","humra.chadwick1@nhs.net",{"name":117,"role":31,"phone":18,"phoneExt":18,"email":18},"Vivi Riga",{"facility":119,"status":18,"city":104,"state":18,"zip":120,"country":46,"countryCode":47,"cosmosGeoPoint":121,"geoPoint":123,"contacts":124},"King's College Hospital","SE5 9RS",{"type":49,"coordinates":122},[108,109],{"lat":109,"lon":108},[125,127,130,131],{"name":126,"role":35,"phone":36,"phoneExt":18,"email":40},"Trial Manager",{"name":128,"role":35,"phone":18,"phoneExt":18,"email":129},"Lisa Ramazzotto","lisa.ramazzotto@nhs.net",{"name":29,"role":31,"phone":18,"phoneExt":18,"email":18},{"name":132,"role":133,"phone":18,"phoneExt":18,"email":18},"Olivia Cundy","SUB_INVESTIGATOR",{"facility":135,"status":18,"city":104,"state":18,"zip":136,"country":46,"countryCode":47,"cosmosGeoPoint":137,"geoPoint":139,"contacts":140},"Hillingdon Hospital","UB8 3NN",{"type":49,"coordinates":138},[108,109],{"lat":109,"lon":108},[141,145,148],{"name":142,"role":35,"phone":143,"phoneExt":18,"email":144},"Kash Khuttan","07930550860","kash.khuttan@nhs.net",{"name":146,"role":35,"phone":18,"phoneExt":18,"email":147},"Samantha Kon","s.kon@nhs.net",{"name":149,"role":31,"phone":18,"phoneExt":18,"email":18},"Sheena George",{"type":151,"investigatorFullName":18,"investigatorTitle":18,"investigatorAffiliation":18,"oldNameTitle":18,"oldOrganization":18},"SPONSOR",[153],{"name":30,"class":6},"100652019","mindfulness-for-central-serous-chorioretinopathy-100652019",false,"NCT07767058","Mindfulness for Central Serous Chorioretinopathy","A Pilot Randomised Controlled Trial of a Disease-specific Mindfulness-based Therapy for Central Serous Chorioretinopathy","MIND'S EYE","INCLUSION CRITERIA:\n\nCSCR Cases:\n\n1. Adults (\\> 18 years old)\n2. Active foveal centrepoint-involving CSCR\n3. Diagnosis based on history, examination and OCT scan ± FFA\n4. Central sub-foveal subretinal fluid on OCT scan\n5. First episode or a distinct recurrent episode\n6. Duration of current episode \\\u003C 180 days\n\nNon-CSCR Cases:\n\n1. Adults (\\> 18 years old)\n2. Approximately age- and sex-matched to CSCR cases\n3. No CSCR\n4. No other BCVA-affecting ocular disease or condition\n\nEXCLUSION CRITERIA:\n\nStudy eye:\n\n1. Any treatment for current or previous CSCR with PDT or laser\n2. Use of any topical medication for CSCR currently, or in the last 90 days\n3. Use of topical steroids or carbonic anhydrase inhibitors currently, or in the last 90 days\n4. Intraocular anti-VEGF therapy in the last 180 days\n5. Intraocular steroids in the last 180 days or intraocular steroid implant in the last 3 years\n6. Treatment with retinal or macular laser (except peripheral laser retinopexy at least 90 days prior)\n7. Cryotherapy within 90 days\n8. Previous cyclodiode therapy\n9. Laser refractive surgery within 90 days\n10. Intraocular surgery within 90 days\n11. Presence of any other disease that could cause retinal or subretinal fluid (e.g. diabetic retinopathy, exudative age-related macular degeneration, or polypoidal choroidal vasculopathy)\n12. Current or prior retinal or choroidal neovascularisation of any cause\n13. Diabetic retinopathy\n14. Presence of any other disease which is thought to be currently affecting BCVA, or likely to do so during study participation\n15. Media opacity precluding fundus examination and\u002For imaging (e.g. dense cataract)\n\n    General:\n16. Current, recent (within 90 days) or anticipated (during study participation) treatment with systemic anti-VEGF therapy or oral\u002Fintravenous\u002Fintramuscular steroids\n17. Current or recent (within 90 days) practice of regular (more than twice per week) meditation or mindfulness\n18. Current or recent (within 90 days) use of systemic carbonic anhydrase inhibitors\n19. Unable, unwilling or unlikely to undertake study activities\n20. Any condition which, in the opinion of the investigator, would prevent the participant from granting informed consent or complying with the protocol, such as dementia, mental illness, or serious systemic medical disease\n\nWhere potential CSCR participants present with both eyes meeting the above criteria, one eye only will be included in the study. The eye with the greatest central 1 mm subfield thickness (µm) on OCT imaging will be the study eye. In these participants, data on the fellow affected eye in the study will still be collected, to allow the possibility of looking at the symmetry of outcomes between eyes of an individual, but will not be included in formal statistical analysis.",true,"ALL","18 Years",{"count":166,"type":167},100,"ESTIMATED","INTERVENTIONAL",[170],"NA","The primary goal of this clinical trial is to test whether a mindfulness-based treatment is effective at shortening the duration of, and improving the features of, central serous chorioretinopathy in adults. Researchers will compare adults with central serous chorioretinopathy who undertake an 8 week mindfulness-based treatment course, with those who do no mindfulness, to see if mindfulness improves time to disease resolution and disease features.\n\nThe secondary goal of this clinical trial is to compare adults with central serous chorioretinopathy to adults with healthy eyes across a variety of stress-related factors, and also measure the change in some of these factors, if any, caused by mindfulness.\n\nThe questions this clinical trial aims to answer are:\n\n* is mindfulness effective at improving the clinical course of central serous chorioretinopathy?\n* is a mindfulness-based treatment programme for central serous chorioretinopathy acceptable to adults with the disease?\n* if effective, does mindfulness alter any stress-related psychological or biological features in adults with central serous chorioretinopathy?\n* what are the stress-related psychological and biological features of adults with central serous chorioretinopathy, compared to adults with healthy eyes?\n\nParticipants will:\n\n* Undertake daily mindfulness practices for 8 weeks and participate in fortnightly group sessions, or undertake no mindfulness\n* Visit the research clinic once every month for the first six months, and then again at 12 months, for checkups and tests",[173],"Central Serous Chorioretinopathy",[175,176,177,178],"central serous chorioretinopathy","mindfulness","pilot clinical trial","stress","NOT_YET_RECRUITING","2026-08-10",{"date":182,"type":183},"2026-08-17","ACTUAL",{"date":185,"type":167},"2026-10-01",{"date":187,"type":167},"2030-07-31",{"name":5,"class":6},6]